key: cord-0725836-6lxavl5k
authors: Jiang, Hongbo; Chen, Qiaosen; Zheng, Shaoping; Guo, Chunxia; Luo, Jinzhuo; Wang, Hua; Zheng, Xin; Weng, Zhihong
title: Association of Complement C3 with Clinical Deterioration Among Hospitalized Patients with COVID-19
date: 2022-01-26
journal: Int J Gen Med
DOI: 10.2147/ijgm.s348519
sha: d051950a1535212dfadab63baab0f7ce628db627
doc_id: 725836
cord_uid: 6lxavl5k

BACKGROUND: The role of the complement system in coronavirus disease 2019 (COVID-19) remains controversial. This study aimed to evaluate the relationship between serum complement C3 levels, clinical worsening, and risk of death in hospitalized patients with COVID-19. METHODS: Data were collected from 216 adults with COVID-19 admitted to a designated clinical center in Wuhan Union Hospital (China) between February 13, 2020, and February 29, 2020. Their complement C3 levels were measured within 24 h of admission. The primary outcome was a clinical worsening of 2 points on a 6-point ordinal scale. The secondary outcome was all-causes of death. Inverse probability of treatment weighting (IPTW) analysis was conducted to adjust for the baseline confounders. RESULTS: The median value of C3 was 0.89 (interquartile range, 0.78–1.01) g/L. Clinical worsening occurred in 12.3% (7/57) and 2.5% (4/159) of patients with baseline C3 levels < and ≥0.79 g/L, respectively (hazard ratio [HR], 5.22; 95% confidence interval [CI], 1.53–17.86). After IPTW adjustment, the risk for clinical worsening was 4-fold greater (weighted HR, 4.61; 95% CI, 1.16–18.4) in patients with C3 levels less than 0.79 g/L comparatively. The sensitivity analyses revealed the robustness of the results. No significant associations between C3 levels and death were observed on unadjusted (HR, 2.92; 95% CI, 0.73–11.69) and IPTW analyses (weighted HR, 3.78; 95% CI, 0.84–17.04). CONCLUSION: Low complement C3 levels are associated with a higher risk for clinical worsening among inpatients with COVID-19. The serum C3 levels may contribute to the identification of patient populations that could benefit from therapeutic complement inhibition.

The coronavirus disease 2019 (COVID- 19) , which is caused by the severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2), has resulted in a global pandemic and considerable mortality. The fatal outcomes from COVID-19 are attributed mainly to an overactive immune response to the SARS-CoV-2 infection. 1 However, hyperinflammation in patients with COVID-19 remains poorly clarified.

Complement, a critical component of the innate immune system, plays a key role against various pathogens, including bacteria and viruses. However, dysregulated activation of the complement can also lead to severe diseases like thrombotic microangiopathy. 2 It was indicated that complement activation is associated with the pathogenesis of the Middle East respiratory syndrome (MERS) 3, 4 and severe acute respiratory syndrome (SARS), 5 which are caused by coronaviruses similar to SARS-CoV-2. A previous study used a mouse model to demonstrate that complement activation occurred in response to SARS-CoV infection, and mice deficient in C3, a central complement component, had less systemic inflammation. 5 Evidence from recent studies suggests that complement activation may help the pathogenesis of SARS-CoV-2 infection by triggering a severe cytokine storm. 6, 7 However, studies on the role of the complement system in COVID-19 are limited by controversial results. A study showed that low complement C3 levels were associated with poor prognosis in COVID-19 patients. 8 However, Qin et al reported that there were no significant differences in the levels of C3 between the mild and severe groups. 9 Moreover, other data showed that C3 levels cannot predict COVID-19 progression. 10 In this study, our goal was to investigate whether complement C3 level is associated with the risk for clinical worsening or death among inpatients with COVID-19.

In this retrospective cohort study, we collected data from patients with laboratory-confirmed COVID-19 in the Tumor Center, which is a designated clinical center for COVID-19 in the Union Hospital, Tongji Medical College of Huazhong University of Science and Technology (Wuhan, China), between February 13, 2020, and February 29, 2020. We screened patients aged ≥18 y with serum complement C3 levels measured within 24 h of admission. Definite outcomes (discharge or death) were followed up until March 15, 2020 .

Patients included in this study were diagnosed using the guidelines of the Diagnosis and Treatment of Novel Coronavirus Pneumonia issued by the Chinese National Health Commission. 11 Data on demographic characteristics, clinical features, underlying diseases, laboratory examinations, treatments, and clinical outcomes were extracted from the patients' electronic medical records. Two trained physicians (CXG and JZL) evaluated them independently. This study was approved by the Ethics Commission of Tongji Medical College of Huazhong University of Science and Technology in Wuhan (2020-0058). Written informed consent was waived because of the rapidly emerging infectious disease and requirements for epidemic prevention and control. The patients' personal information was de-identified to ensure confidentiality and comply with the Declaration of Helsinki.

The normal values of serum C3 levels may vary slightly among different laboratories. The normal value ranged from 0.80 to 1.78 g/L, 12 0.88 to 2.01 g/L, 13 or 0.80 to 1.60 g/L. 14 Some laboratories showed normal values ranging between 0.88 and 2.52 g/L and 0.88 and 2.06 g/L for men and women, respectively. 15 In our hospital, the reference range of serum complement C3 levels was 0.79-1.52 g/L for both men and women. The participants were divided into two groups based on their serum complement C3 levels tested at baseline. Patients with C3 levels less than 0.79 g/L were in the low C3 group and those with C3 levels of 0.79 g/L or greater were in the control group. The study baseline for each patient was 24 h after hospital admission.

Potential confounding factors were chosen according to previously published articles and physician advice, including demographics (age and gender), comorbidities (hypertension, coronary heart disease [CHD], and diabetes), laboratory findings (neutrophils, lymphocytes, C-reactive protein [CRP] , and D-dimer), and medications (arbidol, interferon α-2b, ribavirin, antibiotics, low molecular weight heparin, and Chinese medicine).

The primary outcome was clinical worsening, which was defined as all-causes of death during the hospital stay, or an increase of at least 2 points from baseline on the 6-point ordinal scale, 16 invasive ventilation or extracorporeal membrane oxygenation; and 6 = death. 16 The secondary outcome was only allcauses of death.

Categorized variables were summarized using frequency and proportion. Continuous variables were summarized using the mean and standard deviation. We used absolute standardized mean difference (aSMD) for evaluating the balance between the low C3 and control groups.

We conducted the univariate analysis to establish the relationship between low C3 and clinical worsening. In observational studies, univariate analysis is not reliable enough. Therefore, inverse probability treatment weighting (IPTW) was applied for adjusting variables to keep them comparable between the two groups. 17 Meanwhile, two survival curves were generated using the Kaplan-Meier method. One was based on univariate survival analysis and the other was adjusted using IPTW analysis. For examining the robustness of the results, we performed a series of sensitivity analyses: (1) excluding the different combinations of variables that were included in the primary analysis model; (2) trimming the extreme value of weights. Then, we re-conducted the IPTW analysis. Besides clinical worsening, we explored the relationship between overall survival and low C3 with crude and IPTW analyses using the Cox proportional-hazards regression model. The formula for the IPTW modeling is provided in the Supplementary Methods.

Missing data were handled using multiple imputations. Proportional hazards assumption was verified using Schoenfeld residuals test, and no evidence of violation was found. All statistical analyses were performed using the software R version 4.0.2 (https://www.r-project.org/).

A total of 955 patients with COVID-19 were admitted to this designated clinical center between February 13, 2020, and February 29, 2020. Among them, 728 had no information regarding serum complement C3 levels in their electronic medical records, and 11 were not tested within the 24 h window. Therefore, 216 patients with C3 levels measured within 24 h of admission were included in this study ( Figure 1 ). The median value of C3 level was 0.89 (interquartile range [IQR], 0.78-1.01) g/L. Of the 216 patients, 57 (26.4%) and 159 (73.6%) had C3 levels < and ≥0.79 g/L, respectively. The baseline demographics and clinical characteristics of the low C3 and control groups are summarized in Table 1 . 

Over a median follow-up of 29.1 d (IQR, 28.6-31.2 d), the secondary outcome developed in eight (3.7%) of the 216 patients. Four patients died in both the low C3 (0.081 case/person-month) and control groups (0.027 case/person-month). At the end of the follow-up on 15 March 2020, 205 (94.9%) patients were discharged alive, and three (1.4%) remained in the hospital. Figure 3 shows the Kaplan-Meier curves. Both the unadjusted (HR, 2.92; 95% CI, 0.73-11.69) and IPTW analyses (weighted HR, 3.78; 95% CI, 0.84-17.04) showed insignificant differences between the two groups. However, they indicated that the low C3 population might be associated with a higher risk of death.

Sensitivity analysis for the primary outcome was robust under different contexts of the model. Some important variables, including D-dimer, CRP, diabetes, CHD, and hypertension, were excluded intentionally and the conclusion remained unchanged (Table 2) . Therefore, it is rational to assume that the bias would have been less even if we neglected these variables in the primary analysis. Moreover, we added the weight-trimming analysis to simulate a scenario where the positivity assumption did not hold up and found that the estimate was still robust (Table 2) . 

It has been hypothesized that complement activation may contribute to the pathogenesis of COVID-19. Our study provides clinical evidence based on real-world data to support such a theoretical perspective. In this observational study, we investigated the relationship between serum complement C3 levels, clinical worsening, and risk of death in a retrospective cohort of 216 hospitalized patients with confirmed COVID-19. Our results suggested that in COVID-19 patients who have baseline C3 levels <0.79 g/L, there was a 4-fold greater increase in the risk for clinical worsening when compared to patients with C3 levels ≥0.79 g/L (weighted HR, 4.61; 95% CI, 1. 16-18.4) . The sensitivity analyses revealed the robustness of the results as well.

The complement system, a bridge between innate and adaptive immunity, can identify and eliminate invading viruses through opsonization, promoting virus-specific immune responses and neutralizing cell-free viruses. 18, 19 After activation, the mature complement C3 is cleaved to generate C3a and C3b. Further cleavage of C3b produces iC3b, C3f, C3c, C3dg, C3d, and C3g. 20 C3 acts as a point of convergence among the three complement pathways and plays a central role in the process of complement activation. This results in the amplification of the complement response and helps coordinate downstream immune responses. It has become evident that C3 participates in clearing pathogens and a variety of homeostatic processes, such as tissue regeneration and controlling tumor progression. 21 Hypocomplementemia was considered to be associated with the consumption of complement components because of complement activation. 22 The levels of C3 (not C4) reportedly decreased significantly in patients with septic shock compared to critically ill patients. 23 Similarly, hypocomplementemia was demonstrated in various viral infections, such as parvovirus B19, Ebola virus, and hepatitis C. 24−26 C3 consumption was described in two children with SARS-CoV-2-induced Kawasaki-like hyperinflammatory syndrome. In Phase 2 of their illness, both patients developed progressive thrombocytopenia, hepatomegaly, and diffuse edema. Fortunately, they improved after corticosteroid treatment. 27 Another study reported that very low C3 levels were observed in a child with pediatric inflammatory multisystem syndrome because of SARS-COV-2 infection. After being treated with high-dose intravenous immunoglobulin and methylprednisolone, the child recovered and the C3 levels returned to normal. 28 These studies suggest that complement activation by C3 hypocomplementemia may be implicated in the pathophysiology of COVID-19.

A retrospective study showed that serum complement C3 levels cannot predict COVID-19 progression. 10 In contrast, Fang et al reported that decreased complement C3 was correlated with increased odds of death. 8 However, in the study by Fang et al, adjustment was only performed for age, sex, laboratory findings, and comorbidities. The lack of adjustment for 854 treatment regimens could affect the prognosis of the patients, resulting in a confounding bias. It was reported that plasma levels of complement C3 are associated with the development of hypertension, 29 diabetes, 30 and coronary heart disease. 31 This may account for the higher comorbidity in the control group with relatively higher C3 levels. Therefore, we adjusted for confounders using the IPTW method, including age, sex, comorbidities, laboratory tests, and medications on admission. According to the Cox regression analysis with IPTW, there was a significant inverse correlation between C3 hypocomplementemia and clinical worsening in patients with COVID-19. A series of sensitivity analyses also generated supportive evidence. Moreover, our results indicate that the low C3 population might be experiencing a higher risk of death. No significant associations were observed between the baseline C3 levels and death in the unadjusted and IPTW analyses. Emerging evidence suggests that complement C3 activation might be triggered by virus nucleocapsid protein through virus-released pathogen-associated molecular patterns during SARS-CoV-2 infection. 32, 33 Complement and tissue factor (TF)-enriched neutrophil extracellular traps (NETs) are crucial drivers of immunothrombosis. Moreover, C3 blockade can disrupt TF expression in neutrophils, inhibit complement activation, and attenuate platelet-mediated NET-induced thrombogenicity in COVID-19. 9 Compstatin, a highly selective C3 inhibitor, can inhibit complement activation by binding to C3 and interfering with the convertase formation and C3 cleavage. 34, 35 The latest study reported that treatment with the compstatin was safe and successful in a patient with severe acute respiratory distress syndrome (ARDS) following SARS-COV-2 infection. 36 Another exploratory study in small independent cohorts of severe COVID-19 patients indicated that C3 inhibitor (AMY-101) can abrogate COVID-19 hyperinflammation. This results in the decline of CRP and IL-6 levels, improvement of lung function, and resolution of SARS-CoV-2-associated ARDS. 37 These early clinical results support the evaluation of C3-targeting agents as COVID-19 therapeutics in large prospective trials. The results of our study suggest that the complement system is activated by the consumption of C3 during SARS-CoV-2 infection, and COVID-19 patients with C3 hypocomplementemia might benefit from complement inhibition treatment.

There are several limitations to our study. First, this is a single-center observational study with small sample size. Therefore, the results cannot be generalized, and large-scale randomized controlled trials are warranted to assess the associations of C3 hypocomplementemia with clinical worsening and outcomes of COVID-19. Second, all patients with COVID-19 in this designated clinical center were transferred from other hospitals during the outbreak in Wuhan, and the timing of serum C3 level measurement may be inappropriate for indicating the status of complement activation because each patient was at a different stage of the SARS-COV-2 infection on admission. The longitudinal C3 levels could describe the course of complement activation more accurately compared to the values obtained at baseline. According to the dynamic changes in C3 levels, a reasonable determination can be made regarding the optimal time window for complement intervention. Third, in this designated clinical center, the serum complement C3 level was not routinely measured within 24 h of admission for every COVID-19 patient. Only patients with C3 levels tested at baseline were considered for this study, which might introduce a certain kind of selection bias.

In this preliminary study, our results suggest that low serum complement C3 level is associated with a higher risk for clinical worsening among hospitalized patients with COVID-19. We hypothesize that the C3 level may contribute to the identification of patient populations that could benefit from therapeutic complement inhibition.

Pathophysiology, transmission, diagnosis, and treatment of coronavirus disease 2019 (COVID-19): a review

The complement system: history, pathways, cascade and inhibitors

Blockade of the C5a-C5aR axis alleviates lung damage in hDPP4-transgenic mice infected with MERS-CoV

Complement receptor C5aR1 inhibition reduces pyroptosis in hDPP4-transgenic mice infected with MERS-CoV

Complement activation contributes to severe acute respiratory syndrome coronavirus pathogenesis. mBio

Rationale for targeting complement in COVID-19

Complement and tissue factor-enriched neutrophil extracellular traps are key drivers in COVID-19 immunothrombosis

Decreased complement C3 levels are associated with poor prognosis in patients with COVID-19: a retrospective cohort study

Dysregulation of immune response in patients with coronavirus 2019 (COVID-19

Clinical features and treatment of 2019-nCov pneumonia patients in Wuhan: report of a couple cases

Guidelines of the diagnosis and treatment of novel coronavirus pneumonia (trial version 8). in Chinese

The complex nature of serum C3 and C4 as biomarkers of lupus renal flare

UCSF Benioff Children's Hospitals; 2022

C3 And C4 Blood Test

Compassionate use of remdesivir for patients with severe COVID-19

Prognostic score-based balance measures can be a useful diagnostic for propensity score methods in comparative effectiveness research

Complement and the regulation of T cell responses

A phylogenomic data-driven exploration of viral origins and evolution

Structures of complement component C3 provide insights into the function and evolution of immunity

Complement component C3 -the "Swiss Army Knife" of innate immunity and host defense

Antiphospholipid syndrome: pathogenesis

Alterations in C3, C4, factor B, and related metabolites in septic shock

Hypocomplementemia is a diagnostic clue for parvovirus B19 infection in adults

Lectin-dependent enhancement of Ebola virus infection via soluble and transmembrane C-type lectin receptors

Hypocomplementemia associated with hepatitis C viremia in sera from voluntary blood donors

SARS-CoV-2-induced Kawasaki-like hyperinflammatory syndrome: a novel COVID phenotype in children

Pediatric inflammatory multisystem syndrome with central nervous system involvement and hypocomplementemia following SARS-COV-2 infection

Plasma levels of complement C3 is associated with development of hypertension: a longitudinal cohort study

Complement C3 is a risk factor for the development of diabetes: a population-based cohort study

Complement C3 and C4 in plasma and incidence of myocardial infarction and stroke: a population-based cohort study

Complement as a target in COVID-19?

Highly pathogenic coronavirus N protein aggravates lung injury by MASP-2-mediated complement over-activation. medRxiv

Compstatin: a C3-targeted complement inhibitor reaching its prime for bedside intervention

Clinical promise of next-generation complement therapeutics

The first case of COVID-19 treated with the complement C3 inhibitor AMY-101

Complement C3 vs C5 inhibition in severe COVID-19: early clinical findings reveal differential biological efficacy

The International Journal of General Medicine is an international, peer-reviewed open-access journal that focuses on general and internal medicine, pathogenesis, epidemiology, diagnosis, monitoring and treatment protocols. The journal is characterized by the rapid reporting of reviews, original research and clinical studies across all disease areas. The manuscript management system is completely online and includes a very quick and fair peer-review system

We thank all health care workers in the Department of Infectious Diseases, Union Hospital, Tongji Medical College, Huazhong University of Science and Technology in Wuhan. We acknowledge all the medical staff on the front line in Wuhan. We also thank Bullet Edits for its linguistic assistance during the preparation of this manuscript.

There is no funding to report. 

The authors report no conflicts of interest in this work.